

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

In re Application of

Application Number

Filed

Group Art Unit

Examiner

07-155943 Feb 16-88

Paper No. _____

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

___ (A) referred to in United States Patent Number 5,284,931, column _____

___ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____

___ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or

___ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Saeed Luus

Signature

8-3-00

Date

Typed or printed name

FOR PTO USE ONLY

Approved by: _____
(Initials)

Unit: _____

#4
8-3-00
RP

RECEIVED
FEB 16 2000
1600/2900



US005284931A

United States Patent [19]

Springer et al.

[11] Patent Number: **5,284,931**
 [45] Date of Patent: **Feb. 8, 1994**

[54] INTERCELLULAR ADHESION MOLECULES, AND THEIR BINDING LIGANDS

[75] Inventors: Timothy A. Springer, Newton, Mass.; Robert Rothlein; Steven D. Marlin, both of Danbury, Conn.; Michael L. Dustin, University City, Mo.

[73] Assignee: Dana Farber Cancer Institute, Boston, Mass.

[21] Appl. No.: 515,478

[22] Filed: Apr. 27, 1990

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 456,647, Dec. 22, 1989, which is a continuation-in-part of Ser. No. 45,963, May 4, 1987, which is a continuation-in-part of Ser. No. 115,798, Nov. 2, 1987, which is a continuation-in-part of Ser. No. 155,943, Feb. 16, 1988, which is a continuation-in-part of Ser. No. 189,815, May 3, 1988, which is a continuation-in-part of Ser. No. 230,446, Sep. 28, 1988, which is a continuation-in-part of Ser. No. 324,481, Mar. 16, 1989, which is a continuation-in-part of Ser. No. 373,882, Jun. 30, 1989, which is a continuation-in-part of Ser. No. 456,647, Dec. 22, 1989.

[51] Int. Cl.³ A61K 39/395
 [52] U.S. Cl. 424/85.8; 530/388.22;
 530/395; 530/808; 530/868; 514/8
 [58] Field of Search 424/85.8, 85.91;
 530/387, 389, 808, 388.22

[56] References Cited PUBLICATIONS

Cunningham C, et al., *TIBTECH* 10, Apr., 1992, "Anti-body engineering—how to be human."
 Daniel, J., et al., *Curr. Opin. Immunol.* 3:740-747 (1991), "Use of Monoclonal antibodies in human transplantation."
 Flavin, T., et al., *Transpl. Proc.* 23(1):533-534 (Feb. 1991) "Monoclonal antibodies against intercellular adhesion molecule 1 prglong caroige allograft survival in CY momolgus monkeys."
 Gibbs, W. W., *Scientific American* (Jul. 1993), "Try, try again," pp. 101-103.

Harns, W. J., et al. *Tibtech* 11 (Feb. 1993), pp. 42-44. "Therapeutic antibodies—the coming of age."
 Haug, C. E., et al., *Transplantation* 55:766-773, (Apr. 1993), "A Phase I trial of immunosuppression with anti-, cam-12 (CD54) m Ab in renal allograft recipients."
 Ortho Multicenter Transplant Study Group, *New Engl. J. Med.* 313:337-341 (Aug. 8, 1985).
 Physician's Desk Reference (1993), pp. 1702-1703. "Orthoclone OKT3".
 Marlin, S. D. et al. 1987. *Cell* 51: 813-819. "Purified Intercellular Adhesion Molecule-1 . . ."
 Rothlein, R. et al. 1986. *J. Immunol.* 137:1270-1274. "A Human Intercellular Adhesion Molecule (ICAM-1) . . ."
 Dustin, M. L. et al. 1986. *J. Immunol.* 137(1):245 "Induction by IL1 and Interferon-8: . . ."
 Cosimi et al., *J. Immunol.* 144(12):4604-4612 (1990).
 Flavin et al., *Transplant. Proc.* 23(1):553-534 (1991).
 Tolksoff-Rubin et al., *J. Amer. Soc. Nephrology* 2(3):820 No. 2P (1991).
 Kavanaugh et al., *56th Meeting of Amer. College of Rheumatology*, Oct. 13-15, Atlanta, Ga. (1992).
 Boyd et al., *Proc. Natl. Acad. Sci. USA* 85:3095-3099 (1988).

(List continued on next page.)

Primary Examiner—Christine M. Nucker
 Assistant Examiner—Thomas Cunningham
 Attorney, Agent, or Firm—Sterne, Kessler, Goldstein & Fox

ABSTRACT

[57] Pharmaceutical compositions comprising antibodies to intercellular adhesion molecule-1 (ICAM-1 or CD54) are useful in methods of decreasing the severity of inflammation associated with the adhesion of leukocytes to cells bearing ICAM-1. Treatment with anti-ICAM-1 antibodies reduced the severity of inflammation associated with acute organ or tissue rejection and prolonged allograft survival time. Such compositions may optionally contain other immunosuppressive agents.

11 Claims, 23 Drawing Sheets

To: Henry
 #905271